Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

Overview:

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy that presents significant diagnostic and treatment challenges. While tagraxofusp remains the only approved therapy, an expanding CD123-directed pipeline—including pivekimab sunirine, bispecific antibodies, and CAR T-cell therapies—is reshaping the treatment landscape and creating a need for clinicians to stay current with emerging evidence.

This Medical Crossfire^® program will feature expert-led, case-based discussions on diagnosis, frontline treatment strategies, emerging CD123-directed therapies, and multidisciplinary care. The debate-driven format will help clinicians interpret new data and apply evolving evidence to the management of patients with BPDCN.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Differentiate BPDCN from clinically and pathologically overlapping entities using integrated immunophenotypic, cytogenetic, and molecular criteria
• Compare efficacy and toxicity profiles of FDA-approved and investigational therapies when prioritizing frontline and relapsed/refractory treatment options
• Implement evidence-based protocols for capillary leak syndrome prevention and management while preserving treatment intensity in patients with BPDCN
• Integrate transplant referral, clinical trial enrollment, and multidisciplinary supportive care into BPDCN treatment plans tailored for older adults, pediatric and AYA patients, and patients with CNS involvement

Target Audience:

This educational activity is directed toward hematologist-oncologists, advanced practice providers, nurses, NPs/PAs, pharmacists, dermatopathologists, hematopathologists, and other HCPs involved in the diagnosis and treatment of BPDCN.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.